SCHEMBL4337133

SCHEMBL4337133

Cc1ccc(-c2noc(NC(=O)Cc3ccccc3)c2-c2ccncc2)o1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.67
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
PRKACA P17612 1/20 0.43
ROCK1 Q13464 1/20 0.43
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
PPARG P37231 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4330085 0.90 MAPK14 (0.68) MAPK14PTGS1PTGS2ALDH1A1HPGD
SCHEMBL4333545 0.87 MAPK14 (0.58) MAPK14PTGS1PTGS2
SCHEMBL4332734 0.86 MAPK14 (0.87) MAPK14PRKACAROCK1ALDH1A1POLB
SCHEMBL4328430 0.84 MAPK14 (0.80) MAPK14PRKACAROCK1SMN1; SMN2
SCHEMBL4333303 0.83 MAPK14 (0.69) MAPK14PRKACAROCK1ALDH1A1POLB
SCHEMBL4341287 0.83 MAPK14 (0.72) MAPK14PRKACAROCK1ALDH1A1POLB
SCHEMBL4340549 0.83 MAPK14 (0.85) MAPK14PRKACAROCK1MEN1KMT2A
SCHEMBL4342410 0.82 MAPK14 (0.74) MAPK14PRKACAROCK1ALDH1A1POLB
SCHEMBL4335680 0.82 MAPK14 (0.70) MAPK14ALDH1A1HPGDHSD17B10MEN1
SCHEMBL4341537 0.82 MAPK14 (0.70) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885PTGS1 139/4885PTGS2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.